Literature DB >> 7989970

Dopamine D2 receptor imaging with iodine-123-iodobenzamide SPECT in idiopathic rotational torticollis.

J Hierholzer1, M Cordes, L Schelosky, W Richter, U Keske, S Venz, W Semmler, W Poewe, R Felix.   

Abstract

UNLABELLED: The cause of idiopathic rotational torticollis (IRT) is not completely understood to date. However, basal ganglia are believed to be involved in the pathophysiology of IRT. To elucidate this disorder further, the value of iodobenzamide (IBZM) SPECT was studied for the evaluation of striatal dopamine D2 receptors in these patients.
METHODS: Striatal dopamine D2 receptor density was assessed in 10 patients with IRT using 123I-IBZM SPECT. The images were interpreted by a nuclear medicine physician initially to determine IBZM binding within the striatum and the cerebellum and, secondly, interstriatal IBZM binding. The results were correlated with the clinical parameters of the patients and compared with the results obtained from normal controls.
RESULTS: No difference was found in average, specific striatal IBZM binding (basal ganglia/cerebellum ratio) between patients and controls. However, interstriatal analysis of IBZM binding revealed a significantly higher binding in the striatum contralateral to the direction of the torticollis (p = 0.026, by chi-square test).
CONCLUSION: It was concluded that the striatal dopamine D2 receptor status is altered in patients with IRT.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7989970

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  10 in total

Review 1.  Convergent mechanisms in etiologically-diverse dystonias.

Authors:  Valerie B Thompson; H A Jinnah; Ellen J Hess
Journal:  Expert Opin Ther Targets       Date:  2011-12-03       Impact factor: 6.902

2.  The subthalamic nucleus in primary dystonia: single-unit discharge characteristics.

Authors:  Lauren E Schrock; Jill L Ostrem; Robert S Turner; Shoichi A Shimamoto; Philip A Starr
Journal:  J Neurophysiol       Date:  2009-10-21       Impact factor: 2.714

3.  Hemodynamic responses are abnormal in isolated cervical dystonia.

Authors:  Brian D Berman; Christopher L Groth; Erica Shelton; Stefan H Sillau; Brianne Sutton; Kristina T Legget; Jason R Tregellas
Journal:  J Neurosci Res       Date:  2019-11-06       Impact factor: 4.164

4.  A new knock-in mouse model of l-DOPA-responsive dystonia.

Authors:  Samuel J Rose; Xin Y Yu; Ann K Heinzer; Porter Harrast; Xueliang Fan; Robert S Raike; Valerie B Thompson; Jean-Francois Pare; David Weinshenker; Yoland Smith; Hyder A Jinnah; Ellen J Hess
Journal:  Brain       Date:  2015-07-27       Impact factor: 13.501

Review 5.  Animal models for dystonia.

Authors:  Bethany K Wilson; Ellen J Hess
Journal:  Mov Disord       Date:  2013-06-15       Impact factor: 10.338

6.  Striatal dopaminergic dysfunction at rest and during task performance in writer's cramp.

Authors:  Brian D Berman; Mark Hallett; Peter Herscovitch; Kristina Simonyan
Journal:  Brain       Date:  2013-10-21       Impact factor: 13.501

7.  A new treatment for focal dystonias: incobotulinumtoxinA (Xeomin®), a botulinum neurotoxin type A free from complexing proteins.

Authors:  Joohi Jimenez-Shahed
Journal:  Neuropsychiatr Dis Treat       Date:  2011-12-23       Impact factor: 2.570

Review 8.  The role of dopamine and dopaminergic pathways in dystonia: insights from neuroimaging.

Authors:  Morvarid Karimi; Joel S Perlmutter
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2015-01-29

9.  The relationship between the dopaminergic system and depressive symptoms in cervical dystonia.

Authors:  E Zoons; M A J Tijssen; Y E M Dreissen; J D Speelman; M Smit; J Booij
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-03-17       Impact factor: 9.236

10.  Differential expression of striatal proteins in a mouse model of DOPA-responsive dystonia reveals shared mechanisms among dystonic disorders.

Authors:  Maria A Briscione; Ashok R Dinasarapu; Pritha Bagchi; Yuping Donsante; Kaitlyn M Roman; Anthony M Downs; Xueliang Fan; Jessica Hoehner; H A Jinnah; Ellen J Hess
Journal:  Mol Genet Metab       Date:  2021-06-02       Impact factor: 4.204

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.